论文部分内容阅读
目的评定恩他卡朋辅助左旋多巴治疗帕金森病的临床疗效。方法入选90例病人,随机分为治疗组48例、对照组42例,2组病人诊断均符合帕金森病的诊断标准,年龄、性别、症状、体征及病程等具有可比性。对照组给予左旋多巴片(美国罗氏制药公司),疗程16周;治疗组给予恩卡他朋(芬兰奥利安集团),左旋多巴片(美国罗氏制药公司),疗程16周。16周后观察临床疗效。结果恩他卡朋组疗效明显优于单用左旋多巴组。结论恩他卡朋辅助左旋多巴治疗帕金森病患者疗效满意,且不良反应少,能明显提高帕金森患者生活质量,有临床应用价值。
Objective To evaluate the clinical efficacy of entecavir-assisted levodopa in the treatment of Parkinson’s disease. Methods Ninety patients were selected and randomly divided into treatment group (n = 48) and control group (n = 42). The diagnosis of two groups of patients was consistent with the diagnostic criteria of Parkinson’s disease, with comparable age, gender, symptoms, signs and course of disease. The control group was given levodopa tablets (Roche Pharmaceutical Company, USA) for 16 weeks. The patients in the treatment group were given entecaptan (Finnish Orion Group) and levodopa tablets (Roche Pharmaceutical Company, USA) for 16 weeks. After 16 weeks to observe the clinical efficacy. Results Entecavir group was significantly better than levodopa alone group. Conclusion Entecavir-assisted levodopa treatment of Parkinson’s disease patients with satisfactory results, and fewer adverse reactions, can significantly improve the quality of life of patients with Parkinson’s disease, has clinical value.